FIELD: biotechnology.
SUBSTANCE: described is a group of inventions including an antisense oligonucleotide targeting an alpha-synuclein (SNCA) transcript, a pharmaceutical composition for treating synucleopathy, and an application of the antisense oligonucleotide or the composition for manufacturing a medicinal product for treating synucleopathy in a subject in need thereof. In one of the variants of implementation, the antisense oligonucleotide has a sequence selected from the group consisting of SEQ ID NO: 276; 278; 325; 328; 326; 329; 330; 327; 332; 333 and 559.
EFFECT: invention expands the range of products for treating synucleopathy.
8 cl, 6 dwg, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASE ASSOCIATED WITH OBESITY, CONTAINING AMPHIREGULIN-SPECIFIC DOUBLE-CHAIN OLIGONUCLEOTIDE STRUCTURE | 2021 |
|
RU2810514C1 |
| NUCLEIC ACID MOLECULES FOR REDUCING THE LEVEL OF PAPD5 OR PAPD7 MRNA FOR TREATING INFECTIOUS HEPATITIS B | 2017 |
|
RU2768699C2 |
| DETERMINATION OF NUCLEIC ACIDS BY AMPLIFICATION BASED ON INCORPORATION INTO CHAIN | 2014 |
|
RU2694976C1 |
| SPECIFIC MICROBIOLOGICAL COMPOSITIONS | 2017 |
|
RU2788091C2 |
| DEEP GLYCATION END PRODUCTS RECEPTOR MODULATORS AND MODULATION | 2020 |
|
RU2820247C2 |
| METHOD OF AMPLIFICATION AND IDENTIFICATION OF NUCLEIC ACIDS | 2019 |
|
RU2811465C2 |
| NEW VARIANT OF GLUTAMINE HYDROLYZING GMP SYNTHASE AND A METHOD OF PRODUCING PURINE NUCLEOTIDE USING IT | 2021 |
|
RU2804010C1 |
| RNA-GUIDED TRANSCRIPTION REGULATION | 2014 |
|
RU2756865C2 |
| POLYVALENT RECOMBINANT SWINE POX VIRUS | 2017 |
|
RU2766008C2 |
| NEW PROMOTER AND ITS USE | 2021 |
|
RU2811953C1 |
